Advances in transcutaneous vaccine delivery: do all ways lead to Rome?

Transcutaneous immunization (TCI) is a promising alternative to vaccine delivery via the subcutaneous and intramuscular routes, due to the unique immunological characteristics of the skin. The increasing knowledge of the skin immune system and the novel delivery methods that have become available have boosted research on new vaccination strategies. However, TCI has not yet been exploited to its full potential, because the barrier function of the stratum corneum, the top layer of the skin, is difficult to overcome. In this review we first discuss the immune system of the skin, focusing on the role the different types of skin residing dendritic cells play in the immune response. Subsequently, adjuvants and the large variety of devices, in particular microneedles, developed to deliver vaccines into the skin are summarized. Clearly, many ways have been explored to achieve efficient transcutaneous vaccination with varying success. The perspectives of the most promising concepts will be discussed.

[1]  J. Bouwstra,et al.  Quantitative assessment of the transport of elastic and rigid vesicle components and a model drug from these vesicle formulations into human skin in vivo. , 2004, The Journal of investigative dermatology.

[2]  R. Langer,et al.  Controlled protein delivery from biodegradable tyrosine-containing poly(anhydride-co-imide) microspheres. , 1997, Biomaterials.

[3]  Mark R Prausnitz,et al.  Coated microneedles for transdermal delivery. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[4]  S. Edgar,et al.  CD14+ antigen-presenting cells in human dermis are less mature than their CD1a+ counterparts. , 2007, International immunology.

[5]  H. Ueno,et al.  Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. , 2008, Immunity.

[6]  A. Banga,et al.  In vitro transdermal delivery of therapeutic antibodies using maltose microneedles. , 2009, International journal of pharmaceutics.

[7]  R. Rappuoli,et al.  Transcutaneous Immunization with Cross-Reacting Material CRM197 of Diphtheria Toxin Boosts Functional Antibody Levels in Mice Primed Parenterally with Adsorbed Diphtheria Toxoid Vaccine , 2008, Infection and Immunity.

[8]  C. Caux,et al.  Human Langerhans Cells Express a Specific TLR Profile and Differentially Respond to Viruses and Gram-Positive Bacteria1 , 2006, The Journal of Immunology.

[9]  M. Kapsenberg,et al.  Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9. , 2007, The Journal of investigative dermatology.

[10]  G. Cevc,et al.  Transdermal immunization with large proteins by means of ultradeformable drug carriers , 1995, European journal of immunology.

[11]  P. Brennan,et al.  CD1-restricted T cell recognition of microbial lipoglycan antigens. , 1995, Science.

[12]  J. Bouwstra,et al.  Structure of the skin barrier and its modulation by vesicular formulations. , 2003, Progress in lipid research.

[13]  R. Rappuoli,et al.  Transcutaneous immunization with tetanus toxoid and mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong protective antibody responses. , 2003, The Journal of infectious diseases.

[14]  V. Kuchroo,et al.  IL-4 inhibits TGF-β-induced Foxp3+ T cells and, together with TGF-β, generates IL-9+ IL-10+ Foxp3− effector T cells , 2008, Nature Immunology.

[15]  Diane E. Sutter,et al.  Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery , 2002, Nature Medicine.

[16]  J. Cross,et al.  Topical resiquimod promotes priming of CTL to parenteral antigens. , 2009, Vaccine.

[17]  T. Geijtenbeek,et al.  Two way communication between neutrophils and dendritic cells. , 2006, Current opinion in pharmacology.

[18]  T. Prow,et al.  The effect of strain rate on the precision of penetration of short densely-packed microprojection array patches coated with vaccine. , 2010, Biomaterials.

[19]  D. Schmitt,et al.  Immunization onto shaved skin with a bacterial enterotoxin adjuvant protects mice against respiratory syncytial virus (RSV). , 2003, Vaccine.

[20]  M. Alter,et al.  An outbreak of hepatitis B associated with jet injections in a weight reduction clinic. , 1990, Archives of internal medicine.

[21]  L. Payne,et al.  Multi-antigenic DNA immunization using herpes simplex virus type 2 genomic fragments , 2008, Human vaccines.

[22]  H. Spits,et al.  Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from TH-17, TH1 and TH2 cells , 2009, Nature Immunology.

[23]  W. Jiskoot,et al.  Immune Modulation by Adjuvants Combined with Diphtheria Toxoid Administered Topically in BALB/c Mice After Microneedle Array Pretreatment , 2009, Pharmaceutical Research.

[24]  N. Lycke,et al.  Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. , 1997, Journal of immunology.

[25]  Sanyog Jain,et al.  Mannosylated niosomes as carrier adjuvant system for topical immunization , 2005, The Journal of pharmacy and pharmacology.

[26]  Leaf Huang,et al.  Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines. , 2007, Molecular immunology.

[27]  S. Muller,et al.  Immunization onto bare skin with heat‐labile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge , 2001, Immunology.

[28]  R. Lavker,et al.  Safety and Immunogenicity of an Enterotoxigenic Escherichia coli Vaccine Patch Containing Heat-Labile Toxin: Use of Skin Pretreatment To Disrupt the Stratum Corneum , 2007, Infection and Immunity.

[29]  Petras Juzenas,et al.  Microneedle-mediated intradermal delivery of 5-aminolevulinic acid: potential for enhanced topical photodynamic therapy. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[30]  W. Jiskoot,et al.  Microneedle-Based Transcutaneous Immunisation in Mice with N-Trimethyl Chitosan Adjuvanted Diphtheria Toxoid Formulations , 2010, Pharmaceutical Research.

[31]  M. Schmuth,et al.  Expression of the C‐C chemokine MIP‐3α/CCL20 in human epidermis with impaired permeability barrier function , 2002, Experimental dermatology.

[32]  S W Hui,et al.  Induction of cytotoxic T-lymphocytes by electroporation-enhanced needle-free skin immunization. , 2006, Vaccine.

[33]  K. Dubin,et al.  Physical disruption of skin during poxvirus immunization is critical for the generation of highly protective T cell-mediated immunity , 2010, Nature Medicine.

[34]  B. Autran,et al.  Control of vaccinia virus skin lesions by long-term-maintained IFN-gamma+TNF-alpha+ effector/memory CD4+ lymphocytes in humans. , 2010, The Journal of clinical investigation.

[35]  Stephen P. Schoenberger,et al.  T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions , 1998, Nature.

[36]  C. Cooper,et al.  CPG 7909, an Immunostimulatory TLR9 Agonist Oligodeoxynucleotide, as Adjuvant to Engerix-B® HBV Vaccine in Healthy Adults: A Double-Blind Phase I/II Study , 2004, Journal of Clinical Immunology.

[37]  G. Matyas,et al.  Skin immunization made possible by cholera toxin , 1998, Nature.

[38]  T. Jakob,et al.  Bacterial DNA and CpG–Containing Oligodeoxynucleotides Activate Cutaneous Dendritic Cells and Induce IL–12 Production: Implications for the Augmentation of Th1 Responses , 1999, International Archives of Allergy and Immunology.

[39]  J. Matriano,et al.  Macroflux® Microprojection Array Patch Technology: A New and Efficient Approach for Intracutaneous Immunization , 2004, Pharmaceutical Research.

[40]  J. Hooper,et al.  Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge , 2006, Vaccine.

[41]  Y. Maa,et al.  Adjuvantation of epidermal powder immunization. , 2001, Vaccine.

[42]  Mark R Prausnitz,et al.  Minimally Invasive Protein Delivery with Rapidly Dissolving Polymer Microneedles , 2008, Advanced materials.

[43]  Samir Mitragotri,et al.  Micro-scale devices for transdermal drug delivery. , 2008, International journal of pharmaceutics.

[44]  J. Banchereau,et al.  Critical role of IL-12 in dendritic cell-induced differentiation of naive B lymphocytes. , 1998, Journal of immunology.

[45]  R. Kennedy,et al.  Smallpox and Vaccinia , 1999 .

[46]  Defining protective responses to pathogens: cytokine profiles in leprosy lesions. , 1991, Science.

[47]  A. Hickey,et al.  Pulmonary vaccine delivery , 2007, Expert review of vaccines.

[48]  J. Oxford,et al.  DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. , 2009, Vaccine.

[49]  G. Belz,et al.  Most lymphoid organ dendritic cell types are phenotypically and functionally immature. , 2003, Blood.

[50]  C. Czerkinsky,et al.  Transcutaneous Immunization with Cholera Toxin B Subunit Adjuvant Suppresses IgE Antibody Responses Via Selective Induction of Th1 Immune Responses 1 , 2003, The Journal of Immunology.

[51]  P. Laurent,et al.  Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. , 2007, Vaccine.

[52]  N. Lycke.  From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1‐DD/ISCOM , 2004, Cellular microbiology.

[53]  P. Crooks,et al.  Flux Across of Microneedle-treated Skin is Increased by Increasing Charge of Naltrexone and Naltrexol In Vitro , 2008, Pharmaceutical Research.

[54]  M. Prausnitz,et al.  Stability Kinetics of Influenza Vaccine Coated onto Microneedles During Drying and Storage , 2010, Pharmaceutical Research.

[55]  V E Schijns,et al.  Immunological concepts of vaccine adjuvant activity. , 2000, Current opinion in immunology.

[56]  Ryan F. Donnelly,et al.  Microneedle-based drug delivery systems: Microfabrication, drug delivery, and safety , 2010, Drug delivery.

[57]  Zhu Guo,et al.  Needle-Free Skin Patch Delivery of a Vaccine for a Potentially Pandemic Influenza Virus Provides Protection against Lethal Challenge in Mice , 2007, Clinical and Vaccine Immunology.

[58]  P. Elias,et al.  Cutaneous barrier perturbation stimulates cytokine production in the epidermis of mice. , 1992, The Journal of clinical investigation.

[59]  M. Kapsenberg.  Dendritic-cell control of pathogen-driven T-cell polarization , 2003, Nature Reviews Immunology.

[60]  H. Benson.  Transfersomes for transdermal drug delivery , 2006, Expert opinion on drug delivery.

[61]  Robert Langer,et al.  Transdermal drug delivery , 2008, Nature Biotechnology.

[62]  W. Jiskoot,et al.  Rational design of nasal vaccines , 2008, Journal of drug targeting.

[63]  R. Clark,et al.  The Vast Majority of CLA+ T Cells Are Resident in Normal Skin1 , 2006, The Journal of Immunology.

[64]  S. Saeland,et al.  Cutaneous dendritic cells. , 2005, Seminars in immunology.

[65]  Dexiang Chen,et al.  Epidermal Powder Immunization Induces both Cytotoxic T-Lymphocyte and Antibody Responses to Protein Antigens of Influenza and Hepatitis B Viruses , 2001, Journal of Virology.

[66]  G. Núñez,et al.  Peptidoglycan Signaling in Innate Immunity and Inflammatory Disease* , 2005, Journal of Biological Chemistry.

[67]  T. Geijtenbeek,et al.  Self- and nonself-recognition by C-type lectins on dendritic cells. , 2004, Annual review of immunology.

[68]  E. Spaun,et al.  The influence of epidermal thickness on transcutaneous oxygen pressure measurements in normal persons. , 1988, Scandinavian journal of clinical and laboratory investigation.

[69]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[70]  S. Akira,et al.  Pathogen Recognition and Innate Immunity , 2006, Cell.

[71]  J. Ting,et al.  CATERPILLER: a novel gene family important in immunity, cell death, and diseases. , 2005, Annual review of immunology.

[72]  A. Brooks,et al.  Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells , 2009, Nature Immunology.

[73]  F. Sallusto,et al.  Heterogeneity of CD4+ memory T cells: Functional modules for tailored immunity , 2009, European journal of immunology.

[74]  J. Pitcovski,et al.  B subunit of E. coli enterotoxin as adjuvant and carrier in oral and skin vaccination. , 2006, Veterinary immunology and immunopathology.

[75]  Mark R Prausnitz,et al.  Precise microinjection into skin using hollow microneedles. , 2006, The Journal of investigative dermatology.

[76]  J. Yoshimitsu,et al.  Self-dissolving microneedles for the percutaneous absorption of EPO in mice , 2006, Journal of drug targeting.

[77]  F. Watt.  Terminal differentiation of epidermal keratinocytes. , 1989, Current opinion in cell biology.

[78]  Mark R. Prausnitz,et al.  Dissolving Polymer Microneedle Patches for Influenza Vaccination , 2010, Nature Medicine.

[79]  B. Narasimhan,et al.  Vaccine adjuvants: current challenges and future approaches. , 2009, Journal of pharmaceutical sciences.

[80]  F. Martinon,et al.  NLRs join TLRs as innate sensors of pathogens. , 2005, Trends in immunology.

[81]  L. Babiuk,et al.  Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[82]  C. Katlama,et al.  Preferential Amplification of CD8 Effector-T Cells after Transcutaneous Application of an Inactivated Influenza Vaccine: A Randomized Phase I Trial , 2010, PloS one.

[83]  E. Menzel,et al.  Two-dimensional elastic properties of human skin in terms of an incremental model at the in vivo configuration. , 1995, Medical engineering & physics.

[84]  J. Bos,et al.  Skin immune system. , 1990, Cancer treatment and research.

[85]  J. Banchereau,et al.  Pyogenic Bacterial Infections in Humans with MyD88 Deficiency , 2003, Science.

[86]  Frank O. Nestle,et al.  Skin immune sentinels in health and disease , 2009, Nature Reviews Immunology.

[87]  C. Alving,et al.  Principles of transcutaneous immunization using cholera toxin as an adjuvant. , 1999, Vaccine.

[88]  J. Bouwstra,et al.  Skin Penetration and Mechanisms of Action in the Delivery of the D2-Agonist Rotigotine from Surfactant-Based Elastic Vesicle Formulations , 2003, Pharmaceutical Research.

[89]  S. Muller,et al.  Decision-making at the surface of the intact or barrier disrupted skin: potential applications for vaccination or therapy , 2005, Cellular and Molecular Life Sciences CMLS.

[90]  G. Heller,et al.  Mature Human Langerhans Cells Derived from CD34+ Hematopoietic Progenitors Stimulate Greater Cytolytic T Lymphocyte Activity in the Absence of Bioactive IL-12p70, by Either Single Peptide Presentation or Cross-Priming, Than Do Dermal-Interstitial or Monocyte-Derived Dendritic Cells1 , 2004, The Journal of Immunology.

[91]  P. Kaye,et al.  Dendritic cells at the host-pathogen interface , 2002, Nature Immunology.

[92]  T. Kupper,et al.  Immune surveillance in the skin: mechanisms and clinical consequences , 2004, Nature Reviews Immunology.

[93]  Michael S Roberts,et al.  Dry-coated microprojection array patches for targeted delivery of immunotherapeutics to the skin. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[94]  R. Tan,et al.  Optimization of epicutaneous immunization for the induction of CTL. , 2003, Vaccine.

[95]  R. Zinkernagel,et al.  The influence of antigen organization on B cell responsiveness. , 1993, Science.

[96]  R. Gupta,et al.  Comparison of adjuvant activities of aluminium phosphate, calcium phosphate and stearyl tyrosine for tetanus toxoid. , 1994, Biologicals : journal of the International Association of Biological Standardization.

[97]  H. Ueno,et al.  Harnessing Human Dendritic Cell Subsets to Design Novel Vaccines , 2009, Annals of the New York Academy of Sciences.

[98]  C. Thompson,et al.  Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. , 1993, Journal of immunology.

[99]  M. Prausnitz,et al.  Cutaneous vaccination using microneedles coated with hepatitis C DNA vaccine , 2010, Gene Therapy.

[100]  J. Bouwstra,et al.  Assembled microneedle arrays enhance the transport of compounds varying over a large range of molecular weight across human dermatomed skin. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[101]  E. Sandström,et al.  Strong HIV-Specific CD4+ and CD8+ T-Lymphocyte Proliferative Responses in Healthy Individuals Immunized with an HIV-1 DNA Vaccine and Boosted with Recombinant Modified Vaccinia Virus Ankara Expressing HIV-1 Genes , 2010, Clinical and Vaccine Immunology.

[102]  G. Ada.  Overview of vaccines. , 1996, Methods in molecular medicine.

[103]  G. Glenn,et al.  Dose sparing with intradermal injection of influenza vaccine. , 2004, The New England journal of medicine.

[104]  Adrian C. Williams,et al.  Skin delivery of 5‐fluorouracil from ultradeformable and standard liposomes in‐vitro , 2001, The Journal of pharmacy and pharmacology.

[105]  Y. Maa,et al.  Epidermal powder immunization of mice and monkeys with an influenza vaccine. , 2003, Vaccine.

[106]  R. Rappuoli,et al.  The LTR72 Mutant of Heat-Labile Enterotoxin of Escherichia coli Enhances the Ability of Peptide Antigens To Elicit CD4+ T Cells and Secrete Gamma Interferon after Coapplication onto Bare Skin , 2002, Infection and Immunity.

[107]  Adrian C. Williams,et al.  Skin Delivery of Oestradiol from Deformable and Traditiona Liposomes: Mechanistic Studies , 1999, The Journal of pharmacy and pharmacology.

[108]  J. Bos,et al.  The 500 Dalton rule for the skin penetration of chemical compounds and drugs , 2000, Experimental dermatology.

[109]  J. Haynes,et al.  Epidermal DNA vaccine for influenza is immunogenic in humans. , 2006, Vaccine.

[110]  R. Coffman,et al.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. , 1989, Annual review of immunology.

[111]  K. Hogquist,et al.  Identification of a novel population of Langerin+ dendritic cells , 2007, The Journal of experimental medicine.

[112]  Mark R Prausnitz,et al.  Insertion of microneedles into skin: measurement and prediction of insertion force and needle fracture force. , 2004, Journal of biomechanics.

[113]  P. Friedmann,et al.  Disappearance of epidermal Langerhans cells during PUVA therapy , 1981, The British journal of dermatology.

[114]  J. Ring,et al.  Toll-like receptor expression in human keratinocytes: nuclear factor kappaB controlled gene activation by Staphylococcus aureus is toll-like receptor 2 but not toll-like receptor 4 or platelet activating factor receptor dependent. , 2003, The Journal of investigative dermatology.

[115]  J. Bos,et al.  Cutting Edge: Loss of TLR2, TLR4, and TLR5 on Langerhans Cells Abolishes Bacterial Recognition1 , 2007, The Journal of Immunology.

[116]  G. Kelsoe.  Studies of the humoral immune response , 2000, Immunologic research.

[117]  Mark R Prausnitz,et al.  Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[118]  D. Liepmann,et al.  In vivo evaluation of a microneedle-based miniature syringe for intradermal drug delivery , 2009, Biomedical microdevices.

[119]  Kanji Takada,et al.  Feasibility of microneedles for percutaneous absorption of insulin. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[120]  Wijaya Martanto,et al.  Microinfusion Using Hollow Microneedles , 2006, Pharmaceutical Research.

[121]  Johann W Wiechers,et al.  Water distribution and related morphology in human stratum corneum at different hydration levels. , 2003, The Journal of investigative dermatology.

[122]  M. Tafaghodi,et al.  Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[123]  Samir Mitragotri,et al.  Immunization without needles , 2005, Nature Reviews Immunology.

[124]  K. Mills,et al.  Manipulating the immune system: humoral versus cell-mediated immunity. , 2001, Advanced drug delivery reviews.

[125]  R. Clark.  Skin-resident T cells: the ups and downs of on site immunity. , 2010, The Journal of investigative dermatology.

[126]  W. Heath,et al.  Dendritic cell subsets in primary and secondary T cell responses at body surfaces , 2009, Nature Immunology.

[127]  N. K. Jain,et al.  Systemic and mucosal immune response induced by transcutaneous immunization using Hepatitis B surface antigen-loaded modified liposomes. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[128]  Conor O'Mahony,et al.  Processing difficulties and instability of carbohydrate microneedle arrays , 2009, Drug development and industrial pharmacy.

[129]  Y. Aramaki,et al.  Toll-like receptor-9 expression induced by tape-stripping triggers on effective immune response with CpG-oligodeoxynucleotides. , 2007, Vaccine.

[130]  R. Pal,et al.  Persistent antibody and T cell responses induced by HIV-1 DNA vaccine delivered by electroporation. , 2008, Biochemical and biophysical research communications.

[131]  R. Vabulas,et al.  Bacterial CpG‐DNA and lipopolysaccharides activate Toll‐like receptors at distinct cellular compartments , 2002, European journal of immunology.

[132]  J. Shiver,et al.  Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex , 2006, Proceedings of the National Academy of Sciences.

[133]  A. Fahr,et al.  Skin penetration enhancement by a microneedle device (Dermaroller) in vitro: dependency on needle size and applied formulation. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[134]  A. Rudensky,et al.  Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. , 2003, Immunity.

[135]  R. Haut.  Biomechanics of Soft Tissue , 2002 .

[136]  G. Leroux-Roels,et al.  Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. , 2008, Vaccine.

[137]  H. Schaefer,et al.  Principles of Percutaneous Absorption , 1980 .

[138]  M. Cormier,et al.  Effect of delivery parameters on immunization to ovalbumin following intracutaneous administration by a coated microneedle array patch system. , 2006, Vaccine.

[139]  W. Hennink,et al.  Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the antigen. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[140]  B. Malissen,et al.  Langerhans cells--revisiting the paradigm using genetically engineered mice. , 2006, Trends in immunology.

[141]  A. Shaw,et al.  Triggering TLR signaling in vaccination. , 2006, Trends in immunology.

[142]  T. D. Connell,et al.  Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by Type I and Type II heat-labile enterotoxins , 2007, Expert review of vaccines.

[143]  K. Porter,et al.  Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys. , 2003, Virology.

[144]  Koichiro Nakamura,et al.  Differential expression and function of Toll-like receptors in Langerhans cells: comparison with splenic dendritic cells. , 2004, The Journal of investigative dermatology.

[145]  Mark R. Prausnitz,et al.  Coating Formulations for Microneedles , 2007, Pharmaceutical Research.

[146]  J. Bouwstra,et al.  Microneedle arrays for the transcutaneous immunization of diphtheria and influenza in BALB/c mice. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[147]  C. Janeway,et al.  Innate immunity: impact on the adaptive immune response. , 1997, Current opinion in immunology.

[148]  G. Cevc,et al.  Transdermal immunisation with an integral membrane component, gap junction protein, by means of ultradeformable drug carriers, transfersomes. , 1998, Vaccine.

[149]  H. Schild,et al.  Cutting Edge: Priming of CTL by Transcutaneous Peptide Immunization with Imiquimod1 , 2005, The Journal of Immunology.

[150]  Massimo Gadina,et al.  Cytokines and Transcription Factors That Regulate T Helper Cell Differentiation: New Players and New Insights , 2003, Journal of Clinical Immunology.

[151]  Ruslan Medzhitov,et al.  Toll-like receptors and innate immunity , 2001, Nature Reviews Immunology.

[152]  F. Hirahara,et al.  Cross-reactive protection against influenza A virus by a topically applied DNA vaccine encoding M gene with adjuvant. , 2005, Viral immunology.

[153]  L. Miller,et al.  Toll-like receptors in the skin , 2007, Seminars in Immunopathology.

[154]  B. Malissen,et al.  Priming of CD8+ and CD4+ T Cells in Experimental Leishmaniasis Is Initiated by Different Dendritic Cell Subtypes1 , 2009, The Journal of Immunology.

[155]  J. Dutz,et al.  Topical TLR9 agonists induce more efficient cross‐presentation of injected protein antigen than parenteral TLR9 agonists do , 2007, European journal of immunology.

[156]  C. Alving,et al.  Transcutaneous immunization: A human vaccine delivery strategy using a patch , 2000, Nature Medicine.

[157]  J. Davoust,et al.  Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. , 2000, Immunity.

[158]  K. Tamaki,et al.  Role of Langerhans cells in cutaneous protective immunity: is the reappraisal necessary? , 2006, Journal of dermatological science.

[159]  T. Ganz,et al.  TGF-α Regulates TLR Expression and Function on Epidermal Keratinocytes1 , 2005, The Journal of Immunology.

[160]  N. Mickuvienė,et al.  Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial , 2009, BMC medicine.

[161]  R. Zeuner,et al.  Differential signaling by CpG DNA in DCs and B cells: not just TLR9. , 2003, Trends in immunology.

[162]  Dinesh Mishra,et al.  Elastic liposomes mediated transcutaneous immunization against Hepatitis B. , 2006, Vaccine.

[163]  P. Ricciardi-Castagnoli,et al.  CpG motifs induce Langerhans cell migration in vivo. , 2000, International immunology.

[164]  Göran Stemme,et al.  Side-opened out-of-plane microneedles for microfluidic transdermal liquid transfer , 2003 .

[165]  C. Janeway,et al.  A human homologue of the Drosophila Toll protein signals activation of adaptive immunity , 1997, Nature.

[166]  Toll-free immunity? , 2008, Nature Medicine.

[167]  Jung-Hwan Park,et al.  Dissolving microneedles for transdermal drug delivery. , 2008, Biomaterials.

[168]  M. Prausnitz,et al.  Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge , 2009, Proceedings of the National Academy of Sciences.

[169]  H. Ueno,et al.  Understanding human myeloid dendritic cell subsets for the rational design of novel vaccines. , 2009, Human immunology.

[170]  G. Vandermeulen,et al.  Effect of Tape Stripping and Adjuvants on Immune Response After Intradermal DNA Electroporation , 2009, Pharmaceutical Research.

[171]  J. Belisle,et al.  Langerhans cells utilize CD1a and langerin to efficiently present nonpeptide antigens to T cells. , 2004, The Journal of clinical investigation.

[172]  S. Abraham,et al.  Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-α , 1996, Nature.

[173]  E. Devilard,et al.  The dermis contains langerin+ dendritic cells that develop and function independently of epidermal Langerhans cells , 2007, The Journal of experimental medicine.

[174]  Fernand Labrie,et al.  Gender differences in mouse skin morphology and specific effects of sex steroids and dehydroepiandrosterone. , 2005, The Journal of investigative dermatology.

[175]  R. Haworth,et al.  Preclinical safety assessment of a DNA vaccine using particle-mediated epidermal delivery in domestic pig, minipig and mouse. , 2006, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[176]  S. Akira,et al.  Macrophages and Myeloid Dendritic Cells, but Not Plasmacytoid Dendritic Cells, Produce IL-10 in Response to MyD88- and TRIF-Dependent TLR Signals, and TLR-Independent Signals1 , 2006, The Journal of Immunology.

[177]  S. Hoffman,et al.  Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes. , 2002, Human gene therapy.

[178]  W. J. Mulholland,et al.  Multiphoton high-resolution 3D imaging of Langerhans cells and keratinocytes in the mouse skin model adopted for epidermal powdered immunization. , 2006, The Journal of investigative dermatology.

[179]  M. Allen,et al.  Microfabricated microneedles: a novel approach to transdermal drug delivery. , 1998, Journal of pharmaceutical sciences.

[180]  G. Matyas,et al.  Needle-Free Skin Patch Vaccination Method for Anthrax , 2004, Infection and Immunity.

[181]  H. Shimizu,et al.  Induction of therapeutically relevant cytotoxic T lymphocytes in humans by percutaneous peptide immunization. , 2006, Cancer research.

[182]  J. Berzofsky,et al.  Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. , 2004, The Journal of clinical investigation.

[183]  F. Sallusto,et al.  Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells , 2000, Nature Immunology.

[184]  Takaya Miyano,et al.  Sugar Micro Needles as Transdermic Drug Delivery System , 2005, Biomedical microdevices.

[185]  P. Laurent,et al.  Cutaneous delivery of prophylactic and therapeutic vaccines: historical perspective and future outlook , 2008, Expert review of vaccines.

[186]  J. Bouwstra,et al.  Improved piercing of microneedle arrays in dermatomed human skin by an impact insertion method. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[187]  G. Glenn,et al.  Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. , 2007, Vaccine.

[188]  Thomas Gebhardt,et al.  Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus , 2009, Nature Immunology.

[189]  C. Katlama,et al.  Transcutaneous Anti-Influenza Vaccination Promotes Both CD4 and CD8 T Cell Immune Responses in Humans1 , 2008, The Journal of Immunology.

[190]  I. Kimber,et al.  Langerhans cells require signals from both tumour necrosis factor‐α and interleukin‐1β for migration , 1997, Immunology.

[191]  G. Glenn,et al.  Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch. , 2005, Vaccine.

[192]  W. Jiskoot,et al.  Transcutaneous Immunization Studies in Mice Using Diphtheria Toxoid-Loaded Vesicle Formulations and a Microneedle Array , 2010, Pharmaceutical Research.

[193]  M. Guan,et al.  Cultured human melanocytes express functional toll-like receptors 2-4, 7 and 9. , 2009, Journal of dermatological science.

[194]  Christoph Wilhelm,et al.  Transforming growth factor-β 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9–producing subset , 2008, Nature Immunology.

[195]  S. Jain,et al.  Transfersomes—A Novel Vesicular Carrier for Enhanced Transdermal Delivery: Development, Characterization, and Performance Evaluation , 2003, Drug development and industrial pharmacy.

[196]  H. Dupont,et al.  Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial , 2008, The Lancet.

[197]  W. Jiskoot,et al.  Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[198]  R. Ward,et al.  Protection of mice against rotavirus challenge following intradermal DNA immunization by Biojector needle-free injection. , 2007, Vaccine.

[199]  R. Compans,et al.  Transcutaneous immunization with inactivated influenza virus induces protective immune responses. , 2006, Vaccine.

[200]  Y. Maa,et al.  Epidermal powder immunization with a recombinant HIV gp120 targets Langerhans cells and induces enhanced immune responses. , 2002, AIDS research and human retroviruses.

[201]  F. Ginhoux,et al.  Blood-derived dermal langerin+ dendritic cells survey the skin in the steady state , 2007, The Journal of experimental medicine.

[202]  L. Turka,et al.  Immunological functions of non-professional antigen-presenting cells: new insights from studies of T-cell interactions with keratinocytes. , 1994, Immunology today.

[203]  J. Reimann,et al.  Modulation of Gene-Gun-Mediated Th2 Immunity to Hepatitis B Surface Antigen by Bacterial CpG Motifs or IL-12 , 2001, Intervirology.

[204]  B. Combadière,et al.  Particle-based vaccines for transcutaneous vaccination. , 2008, Comparative immunology, microbiology and infectious diseases.

[205]  C. Alving,et al.  Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. , 1998, Journal of immunology.

[206]  J. Banchereau,et al.  Influence of the transcription factor RORγt on the development of NKp46+ cell populations in gut and skin , 2009, Nature Immunology.

[207]  M. Prausnitz,et al.  Improved influenza vaccination in the skin using vaccine coated microneedles. , 2009, Vaccine.

[208]  J. Ring,et al.  Various members of the Toll‐like receptor family contribute to the innate immune response of human epidermal keratinocytes , 2005, Immunology.

[209]  F. Brown,et al.  A peptide vaccine administered transcutaneously together with cholera toxin elicits potent neutralising anti-FMDV antibody responses. , 2005, Veterinary immunology and immunopathology.

[210]  D. Weiner,et al.  Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. , 2008, Vaccine.

[211]  R. Steinman,et al.  Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophages. , 2007, The Journal of clinical investigation.

[212]  S. Akira,et al.  A Toll-like receptor recognizes bacterial DNA , 2000, Nature.

[213]  R. Stout,et al.  Hepatitis A vaccine administration: comparison between jet-injector and needle injection. , 2000, Vaccine.

[214]  D. Duffy,et al.  Nanoparticle-based targeting of vaccine compounds to skin antigen-presenting cells by hair follicles and their transport in mice. , 2009, The Journal of investigative dermatology.

[215]  S. Muller,et al.  Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG‐containing oligodeoxynucleotide and effective priming of influenza virus‐specific CD4+ T cells , 2002, Immunology.

[216]  C. Caux,et al.  Macrophage Inflammatory Protein 3α Is Expressed at Inflamed Epithelial Surfaces and Is the Most Potent Chemokine Known in Attracting Langerhans Cell Precursors , 2000, The Journal of experimental medicine.

[217]  Brian W. Barry,et al.  Dermatological Formulations: Percutaneous Absorption , 1983 .

[218]  H. Junginger,et al.  The effect of surfactant-based elastic and rigid vesicles on the penetration of lidocaine across human skin , 2002 .

[219]  Michel Cormier,et al.  Microneedle-based vaccines. , 2009, Current topics in microbiology and immunology.

[220]  S. Mitragotri,et al.  Low-frequency ultrasound as a transcutaneous immunization adjuvant. , 2005, Vaccine.

[221]  M. Hilleman.  Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. , 2000, Vaccine.

[222]  P. Wollan,et al.  Making vaccines more acceptable--methods to prevent and minimize pain and other common adverse events associated with vaccines. , 2001, Vaccine.

[223]  J. Connolly,et al.  Upon viral exposure, myeloid and plasmacytoid dendritic cells produce 3 waves of distinct chemokines to recruit immune effectors. , 2006, Blood.

[224]  N. Weiner,et al.  Transfollicular Drug Delivery , 1995, Pharmaceutical Research.

[225]  V. Ward,et al.  Transcutaneous vaccination with virus-like particles. , 2006, Vaccine.

[226]  J. Pfeilschifter,et al.  TLR-ligand stimulated interleukin-23 subunit expression and assembly is regulated differentially in murine plasmacytoid and myeloid dendritic cells. , 2007, Molecular immunology.

[227]  G. Chang,et al.  Toll-like receptor 7-induced immune response to cutaneous West Nile virus infection. , 2009, The Journal of general virology.

[228]  Chandra Sekhar Kolli,et al.  Characterization of Solid Maltose Microneedles and their Use for Transdermal Delivery , 2007, Pharmaceutical Research.

[229]  D. Mahvi,et al.  A Phase I Study of Immunization Using Particle-Mediated Epidermal Delivery of Genes for gp100 and GM-CSF into Uninvolved Skin of Melanoma Patients , 2007, Clinical Cancer Research.

[230]  C Caux,et al.  CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis. , 1997, Blood.

[231]  I. Toth,et al.  Oral vaccine delivery--new strategies and technologies. , 2009, Current drug delivery.

[232]  Elly van Riet,et al.  Efficient induction of immune responses through intradermal vaccination with N-trimethyl chitosan containing antigen formulations. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[233]  M. Prausnitz,et al.  Transdermal Influenza Immunization with Vaccine-Coated Microneedle Arrays , 2009, PLoS ONE.

[234]  C. Mackay,et al.  T Follicular Helper Cells Express a Distinctive Transcriptional Profile, Reflecting Their Role as Non-Th1/Th2 Effector Cells That Provide Help for B Cells1 , 2004, The Journal of Immunology.

[235]  D. Jarrossay,et al.  Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells , 2009, Nature Immunology.

[236]  A. Iwasaki,et al.  Differential roles of migratory and resident DCs in T cell priming after mucosal or skin HSV-1 infection , 2009, The Journal of experimental medicine.

[237]  C. Alving,et al.  Advances in vaccine delivery: transcutaneous immunisation. , 1999, Expert opinion on investigational drugs.

[238]  K. Palmer,et al.  Chemical conjugate TMV-peptide bivalent fusion vaccines improve cellular immunity and tumor protection. , 2006, Bioconjugate chemistry.

[239]  C. Alving,et al.  Transcutaneous immunization: T cell responses and boosting of existing immunity. , 2001, Vaccine.

[240]  Mark G. Allen,et al.  Polymer Microneedles for Controlled-Release Drug Delivery , 2006, Pharmaceutical Research.

[241]  T. Redelmeier,et al.  Skin Barrier: Principles of Percutaneous Absorption , 1996 .

[242]  G. E. El Maghraby,et al.  Interactions of surfactants (edge activators) and skin penetration enhancers with liposomes. , 2004, International journal of pharmaceutics.

[243]  D. Fuller,et al.  Clinical safety and efficacy of a powdered Hepatitis B nucleic acid vaccine delivered to the epidermis by a commercial prototype device. , 2005, Vaccine.

[244]  C. Janeway,et al.  Innate immune recognition. , 2002, Annual review of immunology.

[245]  P. van Damme,et al.  Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. , 2009, Vaccine.

[246]  Sanyog Jain,et al.  Non-invasive vaccine delivery in transfersomes, niosomes and liposomes: a comparative study. , 2005, International journal of pharmaceutics.

[247]  G. Cheng,et al.  TLR Activation of Langerhans Cell-Like Dendritic Cells Triggers an Antiviral Immune Response1 , 2006, The Journal of Immunology.

[248]  P. Scheinmann,et al.  Vaccine allergy and pseudo-allergy. , 2003, European journal of dermatology : EJD.

[249]  Yvonne Perrie,et al.  Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. , 2008, International journal of pharmaceutics.

[250]  S. Hoffman,et al.  Induction of CD4+ T cell-dependent CD8+ type 1 responses in humans by a malaria DNA vaccine , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[251]  G. Lagoumintzis,et al.  Transcutaneous delivery of a nanoencapsulated antigen: induction of immune responses. , 2010, International journal of pharmaceutics.

[252]  P. Perrin,et al.  Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. , 2005, Immunity.

[253]  Clare L. Bennett,et al.  Murine epidermal Langerhans cells and langerin-expressing dermal dendritic cells are unrelated and exhibit distinct functions , 2009, Proceedings of the National Academy of Sciences.

[254]  D. Busch,et al.  TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. , 2008, Vaccine.

[255]  G. Glenn,et al.  Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch , 2007, Expert review of vaccines.

[256]  H. Ueno,et al.  Dendritic cell subsets in health and disease , 2007, Immunological reviews.

[257]  C. Figdor,et al.  Identification of DC-SIGN, a Novel Dendritic Cell–Specific ICAM-3 Receptor that Supports Primary Immune Responses , 2000, Cell.

[258]  C. Geisler,et al.  The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes , 2007, Immunology.

[259]  Wijaya Martanto,et al.  Mechanism of fluid infusion during microneedle insertion and retraction. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[260]  P. Matzinger.  The Danger Model: A Renewed Sense of Self , 2002, Science.

[261]  Lawrence Steinman,et al.  A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell–mediated tissue damage , 2007, Nature Medicine.

[262]  D. Gebauer,et al.  Hydration-driven transport of deformable lipid vesicles through fine pores and the skin barrier. , 2003, Biophysical journal.

[263]  Vincent J. Sullivan,et al.  Microneedle-Based Intradermal Delivery of the Anthrax Recombinant Protective Antigen Vaccine , 2006, Infection and Immunity.

[264]  I. Frazer,et al.  Potent Immunity to Low Doses of Influenza Vaccine by Probabilistic Guided Micro-Targeted Skin Delivery in a Mouse Model , 2010, PloS one.

[265]  S. Halperin,et al.  A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. , 2003, Vaccine.

[266]  C. Alving,et al.  Transcutaneous Immunization with Bacterial ADP-Ribosylating Exotoxins, Subunits, and Unrelated Adjuvants , 2000, Infection and Immunity.